𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase-II clinical trial of 4′-epi-doxorubicin in advanced solid tumors

✍ Scribed by Andrea Martoni; Michele Giovannini; Luciana Tomasi; Carlo Maurizio Camaggi; Bartolomeo Bellanova; Nino Monetti; Giovanni Rossini; Mario Tarquinii; Alfredo Martini; Franco Pannuti

Publisher
Springer
Year
1984
Tongue
English
Weight
357 KB
Volume
12
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase ii trial of etoposide and doxorubi
Phase ii trial of etoposide and doxorubicin in advanced head and neck cancer
✍ Gradishar, William J. ;Vokes, Everett E. ;Kies, Merrill S. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 388 KB

## Abstract In an effort to improve the response rate of patients with advanced head and neck cancer, a clinical trial combining two infrequently studied drugs was conducted. Twelve patients with squamous cell carcinoma of the head and neck were treated with 3‐day continuous infusions of etoposide

A phase II trial of 5-fluorouracil, doxo
A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma
✍ Susan G. Arbuck; Yusuf Silk Md; Harold O. Douglass Jr.; Hector Nava; Youcef M. R 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB 👁 2 views

To determine the feasibility and toxicity of combining leucovorin (CF) with a 5fluorouracil(5-FU) combination chemotherapy regimen currently accepted by many as standard treatment for gastric cancer, CF (500 mg/m') was administered in combination with the Georgetown S-FU, doxorubicin, and mitomycin

Phase II trial of indicine N-oxide in re
Phase II trial of indicine N-oxide in relapsed pediatric solid tumors
✍ James S. Miser; William A. Smithson; William Krivit; Carla Hughes; Dianne Davis; 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 280 KB

We used indicine N-oxide to treat 46 children with malignant solid tumors: 17 with osteosarcoma, 12 with neuroblastoma, 13 with a brain tumor, and 4 with other miscellaneous tumors. The efficacy and toxicity of the drug was assessed at the dose of 2000 mg/m2/day for five consecutive days. None of th